Carasent AB (publ)APXZF 80 ROA % is 1.26% as of Mar. 2026, which is 7% above its 10-year median of 1.18. GuruFocus rates APXZF with a GF Score™ of 80/100 and a GF Value™ of $0.18. The stock has 3 warning signs investors should review. Among 683 Healthcare Providers & Services companies, Carasent AB (publ) ranks better than 62.37% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Carasent AB (publ)'s annualizedNet Income for the quarter that ended in Mar. 2026 was $1.26 Mil.
Carasent AB (publ)'s average Total Assets over the quarter that ended in Mar. 2026 was $100.10 Mil. Therefore, Carasent AB (publ)'s annualized ROA % for the quarter that ended in Mar. 2026 was 1.26%.
The historical rank and industry rank for Carasent AB (publ)'s ROA % or its related term are showing as below:
APXZF'
s ROA % Range Over the Past 10 Years
Min: -11.63 Med: 1.18 Max: 114.51
Current: 4.1
During the past 13 years, Carasent AB (publ)'s highest ROA % was 114.51%. The lowest was -11.63%. And the median was 1.18%.
APXZF's ROA % is ranked better than 62.37% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 1.77
vs APXZF: 4.10
Carasent AB (publ) (OTCPK:APXZF) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Carasent AB (publ) ROA % Related Terms
Carasent AB (publ) ROA % Historical Data
* Premium members only.
The historical data trend for Carasent AB (publ)'s ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Carasent AB (publ)'s ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carasent AB (publ) ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Carasent AB (publ)'s ROA % distribution charts can be found below:
* The bar in red indicates where Carasent AB (publ)'s ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Carasent AB (publ) (APXZF) has a ROA % of 1.26% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Carasent AB (publ) and its competitors. This is near median its historical median of 1.18. According to the industry distribution chart, Carasent AB (publ) ranks #257 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 37.6%.
Is Carasent AB (publ)'s ROA % too high?
Carasent AB (publ)'s current ROA % of 1.26% is near median its 10-year median of 1.18. The Healthcare Providers & Services industry median ROA % is 1.77. Carasent AB (publ)'s value of 1.26% is 28.8% below this industry median. Based on the distribution chart, Carasent AB (publ) ranks #257 out of 683 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Carasent AB (publ) has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Carasent AB (publ)'s ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Carasent AB (publ) ranks #257 out of 683 companies for ROA %. This puts Carasent AB (publ) in the upper half of its industry. The industry median ROA % is 1.77. Carasent AB (publ)'s value of 1.26% is 28.8% below this benchmark. While the company's 10-year median is 1.18 vs. the industry median of 1.77, Carasent AB (publ) has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.77, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Carasent AB (publ)'s current ROA % of 1.26% is 28.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Carasent AB (publ) and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carasent AB (publ)'s current ROA % is 1.26%, which is near median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carasent AB (publ) stock overvalued right now?
Carasent AB (publ) (APXZF) has a current ROA % of 1.26%. The stock's GF Value™ is $0.18, compared to a current price of $0.15 — trading 16.7% below its estimated fair value. The current ROA % is 1.26%, which is near median its 10-year median of 1.18 and 28.8% below the Healthcare Providers & Services industry median of 1.77. Carasent AB (publ)'s overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Carasent AB (publ) (APXZF), the current ROA % is 1.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carasent AB (publ) (APXZF) Overvalued in 2026?
Based on GuruFocus' analysis, Carasent AB (publ) stock appears to be undervalued.
The current stock price of $0.15 is trading 16.7% below its estimated GF Value™ of $0.18.
Key valuation signals for APXZF:
ROA %: 1.26% (near median its 10-year median of 1.18)
GF Value™: $0.18 vs. price of $0.15 (16.7% below fair value)
Industry Position: 28.8% below the Healthcare Providers & Services median (#257 of 683)
No single metric tells the full story. See the APXZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carasent AB (publ) Formerly Carasent AB is a comprehensive provider of cloudbased EHR solutions and platform services for various organizations within the healthcare sector. With Webdoc as the main product, the group offers a broad ecosystem of services, including solutions for patient communication and business intelligence. Geographically, the company operates in the Nordic region and Germany. It derives maximum revenue from Nordic Region. The solutions provides by the group are: Webdoc; Metodika; Medrave; HPI plustoo; Ad Curis; Ad Opus; Webcur; Data-AL; and Data-Cur.
80GF Score
Get the complete analysis for APXZF
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APXZF has been successfully added to your 
